tetracycline hydrochloride

Phase 2Small molecule

EEuropean Organisation for Research and Treatment of Cancer - EORTC

tetracycline hydrochloride is one of 96 small molecule programs targeting Skin rash. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin RashActive, not recruiting

LymphomaActive, not recruiting

MALT LymphomaActive, not recruiting

Breast CancerActive, not recruiting

Skin RashPreclinical

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

MALT LymphomaPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Tykerb

GSK

Preclinical

80 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

BBio-Thera Solutions

Preclinical

153 7

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 8

Prolia

Amgen

Preclinical

14 9

Gemzar

GGynecologic Oncology Group

Preclinical

22 10

tetracycline hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Skin rash1 trial

Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer

Completed·AAlliance for Clinical Trials in Oncology·N/A·NCT00091247·130 enrolled

MALT lymphoma1 trial

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002682·5 enrolled

Breast Cancer1 trial

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Withdrawn·SSWOG Cancer Research Network··NCT00873808

Lymphoma1 trial

Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00003151·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for tetracycline hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tetracycline hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tetracycline hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

tetracycline hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Skin rash1 trial

MALT lymphoma1 trial

Breast Cancer1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News